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Available online 16 December 2016Background: Despite international efforts to standardize C-peptide and insulin calibrators and immunoas-
says, platform dependent differences still exist, and platform speciﬁc reference intervals are hence needed for
correct interpretation. We therefore wanted to establish traceable reference intervals for C-peptide and insulin.
Methods: In 623 consecutively recruited participants, insulin and C-peptide were measured using the Cobas
e411 (Roche Diagnostics, Switzerland). Participants with diabetes were excluded (fasting Glucose ≥7.0 mmol/L
orHbA1c ≥ 6.5%/ ≥ 48mmol/L) and reference intervalswere calculatedwith andwithout the inclusion of persons
who were prediabetic, according to two deﬁnitions (TheWorld Health Organization (WHO) and American Dia-
betes Association (ADA)). To ensure the correctness of calibration, the control poolswere analyzed by a reference
laboratory. The reference intervals were calculated according to the IFCC guidelines, using the RefVal software
(Solberg, Oslo, Norway).
Results: Comparison of our results with those from the reference laboratory revealed equivalence for C-pep-
tide resultswhereas the insulin determined on the Cobas e411 assaywere 15–20%higher. The difference is attrib-
uted to an incorrect conversion factor for converting from activity to metric units. The Cobas e411 assay uses the
factor 6.945 for converting from U/mL to pmol/L. This is in disagreement with the biological activity of insulin
which is 166.8 × 106 IU/mol or 6.00 nmol/IU.
Conclusion:We successfully established reference intervals for C-peptide and insulin for non-diabetic and
prediabetic participants. The reference intervals for fasting C-peptide and fasting insulin are ready for implemen-
tation. A recertiﬁcation of the insulin standards is needed.
© 2016The Authors. Published by Elsevier Inc. on behalf of The Canadian Society of Clinical Chemists. This
is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Keywords:
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Human insulin is a 5.8 kDa polypeptide produced in the islets of
Langerhans, the endocrine part of the pancreas. Glucose is themost im-
portant regulator of insulin secretion. Insulin is an anabolic hormoneS, Dansk Institut for Ekstern
sh Institute for External Quality
national reference preparation;
iabetes mellitus type 1; DM2,
ting plasma glucose; HbA1c,
umference; WHR, waist-to-hip
Organization; ADA, American
, University of Minnesota.
n),
r Inc. on behalf of The Canadian Sthat lowers blood glucose through stimulation of synthesis of glycogen,
proteins and lipids and inhibition of lipolysis [1]. The 81 amino acid pro-
insulin peptide consists of three domains: an amino-terminal B-chain, a
carboxy-terminal A-chain and a connecting peptide in the middle,
known as the C-peptide. During passage through the endoplasmic retic-
ulum, the precursor folds and the prohormone convertases PC1/3 and -2
subsequently excise the C-peptide, generating the mature form of insu-
lin and C-peptide [2]. C-peptide is stored in beta cells and released by ac-
tive secretion in equimolar amounts to insulin [3]. Only fully matured
insulin from which C-peptide has been removed can interact with the
insulin receptor [4]. The conversion of proinsulin is almost complete,
thus only a small amount of proinsulin is found in the blood. Insulin is
primarily degraded in the liver, whereas 85% of C-peptide, in contrast,
is cleared from circulation by renal ﬁltration [5]. Furthermore, the
half-life of C-peptide is longer than insulin (20–30 and 3–5min, respec-
tively). Hence, the concentration of C-peptide is three to six timesociety of Clinical Chemists. This is an open access article under the CC BY license
409P.B. Larsen et al. / Clinical Biochemistry 50 (2017) 408–413higher than the concentration of insulin. The rate of elimination of insu-
lin depends on multiple metabolic processes leading to great variety in
plasma level, whereas the plasma concentration of C-peptide varies less.
Therefore, the plasma C-peptide concentration is a better measure for
assessing insulin secretion [1].
In the clinic, measurements of C-peptide are mainly used to distin-
guish between diabetes mellitus (DM) type 1 (DM1) and 2 (DM2).
DM is deﬁned as “a group of diseases characterized by hyperglycemia
resulting from defects in insulin secretion, insulin action, or both” [6].
DM1 is caused by beta-cell destruction and leads to absolute insulin de-
ﬁciency. In contrast, DM2 results from insulin resistance and a progres-
sive insulin secretory defect [7]. Prediabetes (PDM) indicates an
increased risk of developing diabetes. Prediabetic patients by deﬁnition
have impaired fasting glucose (IFG) and/or impaired glucose tolerance
(IGT) which are associated with the metabolic syndrome (MetS) [8].
MetS is a group of risk factors together linked to an increased risk of
DM2 and cardiovascular disease: obesity/central obesity, insulin resis-
tance, hypertension and dyslipidemia (hypertriglyceridemia) [9].
Abdominal obesity or adiposity is the key clinical feature in MetS and
seems to precede the other risk factors [10].
Both insulin and C-peptide are usually measured using antibody
based assays. In fact, the radioimmunoassay (RIA) - invented by Yalow
and Berson more than ﬁfty years ago - was ﬁrst used to quantify insulin
[11]. Despite this, the standardization of the calibrators, assays and stan-
dardization of reference intervals is still not complete [12]. An Insulin
StandardizationWorkgroupwas established by ADA in 2004 to address
the issue [13]. Furthermore the preanalytical conditions affecting insu-
lin measurements have been carefully reviewed [14]. The co-determi-
nation of exogenous insulin depends on the type of insulin injected
and must be determined for each product and assay. C-peptide is
often measured in preference of insulin, especially in the case of injec-
tion of exogenous insulin.Measurement of plasma insulin aims to assess
insulin production by the beta cells in diagnosis of insulin producing tu-
mours (insulinoma) or other causes of low blood glucose. In addition,
insulin analysis is used to characterize insulin resistance or to judge
when type 2 diabetics need insulin as supplement to their oral therapy
[1]. Standardization and harmonization is therefore pivotal for clinical
practice in diagnosing and treatment of DM. We wanted to use the
Cobas e411 (Roche®) to establish traceable reference intervals for C-
peptide and fasting insulin.
2. Methods
2.1. Deﬁnitions
While the deﬁnition of diabetes is the same for the WHO and the
American Diabetes association (ADA) [7,15], theWHO and the ADAdef-
initions of prediabetes (PDM) differ from each other. The deﬁnition by
ADA uses lower limits for fasting plasma glucose (FPG) and HbA1c
than WHO. The following reference intervals are calculated for both
non-diabetics as well as prediabetics, according to both WHO and ADA
deﬁnitions (Table 1).
2.2. Study population
The participants were recruited from a follow-up of the health
survey “Helbred2006” (Health2006). The main study was launched in
the summer of 2006 and included 3471 randomly chosen citizensTable 1
The deﬁnitions of pre-diabetes and diabetes used deﬁne the groups of the participants.
Diabetes Fasting plasma glucose (FPG) of ≥7 mmol/L and/or
HbA1c ≥ 6.5%/≥48 mmol/L.
Prediabetes (WHO) FPG ≥ 6.1 mmol/L and/or HbA1c ≥ 6.0%/≥42 mmol/L [15].
Prediabetes (ADA) FPG ≥ 5.6 mmol/L and/or HbA1c ≥ 5.7% [7].(participation rate of 44.7%) living in the suburbs of Copenhagen,
Denmark. Five years later the participants in the former survey was
re-invited and a total of 2308 individuals agreed to a re-examination
in between November 2011 and 2012 [16,17]. Inclusion of the partici-
pants from whom we obtained blood samples was done consecutively,
though at the end of recruitment period we tried to achieve a gender
balance. Blood samples were analyzed between March and August
2012. Pregnant women were excluded from participation, and users of
antihistamine were asked to refrain from these medications three
days prior to the examination, if possible. This also applied to use of in-
halers for lung disease. The Ethics Committee of the Capital Region of
Denmark (code H-3-2011-081) approved the study. The health exami-
nations are thoroughly described by Thuesen et al. [17].
2.3. Sample handling
All participants fasted from midnight and the following morning a
venous blood sample was drawn [17]. The samples were initially stored
at−20 °C for one to four weeks while waiting analysis (expected to be
days/at most 1–2 weeks) and subsequently transferred from−20° to
−80 °C during extended storage time up to six months. The blood sam-
pleswere spun immediately after sampling, theplasma collected, refrig-
erated and stored at −20 °C. Fasting insulin and –C-peptide were
analyzed at StenoDiabetic Center (SDC), Gentofte, Denmark. In addition
measurements of fasting glucose, HbA1c and other biochemical vari-
ables were performed. These included cholesterol and triglycerides,
measured on VITROS® 5600 (Ortho Clinical Diagnostics, Raritan, NJ).
Furthermore, participants' weight, height, waist- and hip circumference
was obtained. Body fat percentage was measured using a Tanita BC-420
MA segmental body composition monitor (Tanita, Tokyo, Japan).
2.4. Insulin and C-peptide assays
C-peptide and insulin were measured using a Cobas e411 (Roche
Diagnostics, Mannheim, Germany) and on an AutoDELFIA (Perkin
Elmer, Turku, Finland) instrument at SDC. Characteristics of both the
C-peptide and fasting insulin assays on Cobas e411 and AutoDELFIA
are listed in Table 2.
2.5. Insulin assays
The samples were analyzed on the Cobas e411 and on the
AutoDELFIA. For the Cobas e411 analysis of insulin, the following reagents
were used: cat. #12017504122, Insulin CalSet, cat. #05341787190,
PreciControl Multimarker, cat. #03609979190 PreciControl Multianalyte,
cat. #11731416190 and#11731416160 PreciControl. A detection interval
from 0.200–1000 μU/mL or 1.39–6945 pmol/L was deﬁned by themanu-
facturer [18]. The assays used for themeasurements on AutoDELFIAwere
B080–101 with a detection limit of 3 pmol/L and measurement interval
3–1000 pmol/L [19].
2.6. C-Peptide assays
The analytical measurement range on the Cobas e411 C-peptide
assay was 0.003–13.3 nmol/L or 0.010–40.0 μg/L. The following
reagents were used: cat. #03184919190, C-peptide CalSet, cat.
#05341787190, PreciControl Multimarker, cat. #03609979190,
PreciControl Multianalyte, cat. #03609987190 Diluent MultiAssay
[20]. The AutoDELFIA assay used was B-081-101 with an analytical
measurement range of 10–6000 pmol/L [21].
2.7. Reference measurements
To ensure correctness of calibration, three reference pools were an-
alyzed both on the AutoDelﬁa at SDC and on Cobas e411 at the Depart-
ment of Laboratory Medicine and Pathology, University of Minnesota,
Table 2
Analytical characteristics of the insulin and C-peptide assays.
The characteristics are those obtained during the study and analysis period.
Asssay Manufacturer Traceability Analytical imprecision,
SDC
Level, pmol/L CV %
C-Peptide Cobas e411, Roche
Diagnostics®
WHO International
Reference Reagent,
IRR 84/510
130
1100
2575
3.0
2.4
3.6
Insulin Cobas e411, Roche
Diagnostics®
WHO IRP 66/304 33
128
739
5.0
4.4
3.9
C-Peptide AutoDELFIA,
Perkin Elmer®
WHO 84/510 113
1092
2489
3.7
2.8
2.3
Insulin AutoDELFIA, Perkin
Elmer®
WHO IRP 66/304 21
74
301
7.0
4.7
3.8
410 P.B. Larsen et al. / Clinical Biochemistry 50 (2017) 408–413Minneapolis (UofMN), Minnesota, USA. These assays have been cali-
brated against the reference methods currently operated by Professor
Daniel T. Stein, Albert Einstein College of Medicine, New York City,
New York, USA.
2.8. Statistics
The RefVal 4.11 software (Solberg, Oslo, Norway) was used to deter-
mine the reference interval according to the International Federation of
Clinical Chemistry (IFCC) guidelines [22]. Reference intervals were cal-
culated using non-parametric method (bootstrapping).
3. Results
3.1. The study population
A total of 2308 participants were included in the follow-up of the
population survey Health2006. Blood samples from 623 of these were
used in this study. Of the 623 participants, 33 were excluded due to
DM; 8 women and 25 men. From the remaining 590 participants, 85
had PDM according to the WHO deﬁnition, and 276 with reference to
the ADA deﬁnition (Fig. 1). Therewas a nearly equal gender distributionFig. 1. Flow-chart outlining the study design and number of participants used for calculating
grouped/excluded according to their FPG and HbA1c-level. Of the 590 participants withou
according to WHO.(men, n = 287 (48.6%), women, n = 303 (51.4%)). Most participants
were 40–69 years old (mean age 54 years).
3.2. Body composition and assessment of nutritional status of the study
population
To characterize the participants according to nutritional status we
calculated BMI and waist hip ratio (WHR). Participants who were not
diabetic nor prediabetic according to the deﬁnition by ADA had a
median BMI 24.5 kg/m2. Mean BMI was 25 kg/m2. In summary our
study population, both men and women, were overweight and the
BMI of the non-diabetic and non-prediabetic participants was slightly
lower. Anthropometric indicators of body fat distribution,waist circum-
ference (WC) and waist hip ratio (WHR) [23] are also associated with
risk of diabetes and could be better indicators to discriminate the partic-
ipantswith diabetes from thosewithout. Still though, both BMI,WC and
WHR were all useful parameters [24]. Cut-off values of WHR vary
among countries, but more variation is found for WC than WHR.
In this study WHR was considered elevated when WHR N 0.85 in
women, and WHR N 0.90 in men [25]. In women the minimum WHR
was 0.68, the median value 0.82 and maximumWHR 1.03. In men the
minimumWHR was 0.78, median 0.93 and maximum 1.13.
We used the intervals 20.1–24.9% of body fat (BF) percentage for
men and 30.1–34.9% for women to deﬁne overweight; correspondently
BF% ≥ 25 in men and ≥35 in women was deﬁned as obesity [23]. The
overall BF% for all participants ranged from 10.2 to 50.9 with a mean
BF% of 35.5 for women, equaling obesity. The male population was
leaner with a median BF% below 25. Still though, the median amount
of body fat found corresponds to overweight; 22.3%. In summary, anal-
yses of the body composition of the participant using BMI,WHR and BF%
revealed that the majority of our population is either overweight or
obese.
3.3. Cholesterol and triglyceride levels
A total blood cholesterol b5.2 mmol/L (b200 mg/dL) is considered
desirable, between 5.2 and 6.2 mmol/L (200–239 mg/dL borderline
high, and N6.2 mmol/L (N240 mg/dL) as high [26]. Triglycerides below
1.7 mmol/L (b150 mg/dL) is recommended by the American Heart As-
sociation, whereas 1.7–2.3 mmol/L (150–199 mg/dL) is borderlinethe reference intervals. With reference to deﬁnitions listed elsewhere, participants were
t DM, almost half of them (47%) had PDM with reference to ADA and only 85 (14%)
Table 3
Correctness of the calibration.
Pool C-Peptide (UofMN)
(pmol/L)
C-Peptide (SDC)
(pmol/L)
Insulin (UofMN)
(pmol/L)
Insulin (SDC)
(pmol/L)
CF 6.0
Insulin (SDC)
(pmol/L)
CF 6.945
Low 126 131 27 29 33
Middle 1060 1110 107 111 129
High 2510 2614 614 641 742
SDC andUofMNreported similar results for C-peptide for all calibration levelswith duplicatemeasurements of each sample. Using the default conversion factor listed in theCobas insert kit
yielded greater values at SDC at all levels. A conversion factor of 6.00 almost eliminated this difference.
411P.B. Larsen et al. / Clinical Biochemistry 50 (2017) 408–413high, 2.3–5.6 (200–499 mg/dl) high and ≥5.6 (≥500 mg/dl) very high
[27]. In only 41% of non-diabetic men and 42% of non-diabetic women
total cholesterol was b5.2 mmol/L and in 17 and 16% it was high. The
majority of both non-diabetic men and women had blood triglyceride
level below the cut off (78% of men, 87% of women). The percentage
of the reference population with elevated levels of triglycerides de-
creased with exclusion of diabetics and prediabetics, from 30.2 to 5.8%
inwomen and from 21.5 to 15.5% inmen. Overall, the reference popula-
tion is overweight /obese and dyslipidemic, whichmatch ﬁndings from
a general Danish population survey [28].3.4. Trueness of instrument calibration
To ascertain the trueness of the calibration we exchanged three
pools with the laboratory at UofMN, USA which also uses the Roche
assay but have calibrated this against the reference methods currently
operated by Randy Little and Daniel T. Stein [29,30].
We found that C-peptide measurements were equivalent but
21% higher values for insulin were determined on AutoDELFIA. We
recalculatedwith a conversion factor of 6.0 equaling the biological activ-
ity of insulin [31] and now similar resultswere found (Table 3). Biaswas
greater when using the 6.945 conversion factor than 6.0: 32 versus 14%
(Fig. 2).3.5. C-Peptide reference intervals
We calculated the reference intervals using bootstrapping as the
distribution of C-peptide measurements were not Gaussian (data not
shown). Reference intervals for C-peptide based on measurements on
Cobas e411 are listed in Table 4.Fig. 2.Method comparison between AutoDELFIA and Cobas e411 plasma insulin measurement
obtained on the Cobas platform using the conversion factor (CF) 6.945 (32% higher results) or3.6. Insulin reference intervals
The distribution of insulin concentrations was not Gaussian either,
so again we used bootstrapping to calculate the reference intervals.
The results of the insulin measurements using both conversion factors
are shown in Table 5, 6 and 7. The Cobas e411 uses a factor 6.945 for
converting (μU/mL × 6.945= pmol/L) [19] (Table 5). Using the conver-
sion factor of 6.00 gave other results (Table 6).We also calculated refer-
ence interval from measurements on AutoDELFIA (Table 7). Detection
limit of the AutoDELFIA was 3 pmol/L, however functional detection
limit of 10 pmol/L was used and results lower than 10 pmol/L were
reported as b10 pmol/L. We calculated different reference intervals for
insulin based on the AutoDELFIA measurements (Table 7). The Insulin
reference intervals become narrower and upper limits decreased with
exclusion of prediabetic participants from the reference population.
Reference intervals for insulin on Cobas e411 determinedwith a conver-
sion factor of μU/mL × 6.0 = pmol/L were much closer to the reference
intervals from the AutoDELFIA measurements than calculations with
conversion factor 6.945.4. Discussion
In this studywe determined reference intervals for C-peptide and in-
sulin, measured on the Roche Cobas e411 for people without DM and
PDM using bootstrapping on a sample of general population of men
and women 18–76 years old who were slightly overweight and hyper-
lipidemic. We also conﬁrmed the previously reported problem when
using the built in factory recommended conversion factor for reporting
the insulin concentration in pmol/L [13,30–33].
The quality of assays is important for both the daily usage and for
portability of the test results. The platform dependency of test resultss. Plasma insulin measurements generated using the AutoDELFIA were compared to those
a CF of 6.00 (14% higher results).
Table 6
Insulin reference interval (factor 6.0) (Cobas e411).
Insulin (pmol/L) 2.5% limit (90% CI),
pmol/L
97.5% limit (90% CI),
pmol/L
n
Without diabetes 16 (14–18) 140 (132–161) 590
Without prediabetes (WHO) 14 (14–17) 126 (117–141) 505
Without prediabetes (ADA) 14 (13–16) 117 (98–132) 304
Table 4
Reference intervals for C-peptide (Cobas e411).
The C-peptide reference intervals depend onwhether prediabetic populations are includ-
ed or not. With exclusion of prediabetic participants the reference interval narrows.
C-Peptide (pmol/L) 2,5% limit (90% CI) 97,5% limit (90% CI) N
Without diabetes 379 (372–414) 1631 (1466–1713) 590
Without prediabetes (WHO) 376 (369–409) 1479 (1311–1649) 505
Without prediabetes (ADA) 372 (341–390) 1299 (1219–1479) 314
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against an isotope dilution measurement procedure (isotope dilution-
liquid chromatography/tandem mass spectrometry (IDMS)) calibrated
by using puriﬁed recombinant insulin [30]. In only four of ten methods
(including the Roche assay, used in our study) ≥ 95% of results were
within the 32% total error allowance for desirable method performance.
Only the Roche® andMercodia® assays showed acceptable error occur-
rence and in general the authors observed increasing tendency towards
biases with lower concentration of insulin. We found a 20% difference
between our insulin measurements and results at the reference labora-
tory. This difference is attributed to an incorrect conversion factor for
converting in the Cobas e411 assay. As noted previously, the Cobase411
assay uses the factor 6.945 when converting from U/mL to pmol/L. This
is in disagreement with the biological activity of insulin which is
166.8 × 106 IU/mol or 6.00 nmol/IU [31]. Both the AutoDELFIA and the
Cobas e411 method are calibrated traceable to the WHO IRP 66/304, a
lyophilized impure preparation of human pancreatic insulin. One
international unit (1 IU) of human insulin is the activity contained in
0.03846 mg of the international standard for human insulin [31]. How-
ever, as early reported the reference preparation contains impurities
(salt, water, desamido insulin and ‘traces’ of proinsulin [31,34]. While
this only has negligible importance for assigned activity it causes a
major error when using the assigned mass to calculate the molar
amounts of the IRP. To facilitate and standardize reporting of insulin
measurements in pmol/L there is a need for having reference prepara-
tions that have been assigned values in concentration. This can be
done in severalways; onepossibility is simply to assign a substance con-
centration to the IRP 66/304. Another could be to develop a new IRP
which have a substance concentration assigned from the start. One
such is the newer Japanese preparation [35]. We therefore urge that ac-
tions are taken to quickly make insulin reference preparations with
assigned concentration available to the manufacturers so that assays
can be correctly calibrated and hence making results portable.
Regarding reference intervals for C-peptide, Little et al. [29] evaluat-
ed inter-assay (nine assays) and inter-laboratory (15 laboratories)
variation and compared results to mass spectrometry method. Forty
serum samples were analyzed, eight at each laboratory. They found
some disagreement between C-peptide results, by different laboratories
and methods, primarily at high C-peptide concentrations. They recom-
mended calibration of C-peptide measurement to a reference method
to increase comparability between laboratories.
Our reference population compares well to the characteristics of the
Copenhagen General Population Study and the General Suburban Popu-
lation Study in which 55.2 and 60.5% were either overweight or obese.
Also total blood cholesterol and triglycerides levels match the ﬁndings
in the two bigger studies [28]. We therefore ﬁnd that the population
matches the average Danish population, making our reference interval
applicable to the Danish and similar populations. Reference intervalsTable 5
Insulin reference intervals (factor 6.945) (Cobas e411).
Insulin (pmol/L) 2.5% limit (90% CI),
pmol/L
97.5% limit (90% CI),
pmol/L
N
Without diabetes 19 (16–21) 161 (152–186) 590
Without prediabetes (WHO) 16 (16–20) 147 (135–174) 505
Without prediabetes (ADA) 16 (15–19) 135 (113–153) 314have also been reported for other ethnic populations. Li et al. [36] gen-
erated a reference interval for insulin in non-diabetic Chinese men
from 1434 fasting serum insulin measurements. Their criteria for inclu-
sion and exclusion were much broader than the Danish survey from
which samples for our study are drawn, e.g. they excluded heavy
smokers. Samples were analyzed on the Roche Cobas® 6000 system
E601 Elecsys module resulting in a reference interval of 1.57–
16.32mU/L (9.4–98 pmol/L). Larsson et al. [37] reported a reference in-
terval for insulin as 1.74–18.27 mU/L (10.4–110 pmol/L) based onmea-
surements on 75 year old females and males with a median BMI 26.2.
This is a little narrower than ours.
A limitation of the current study may be that we classiﬁed partici-
pants solely based on fasting glucose and HbA1c level and not reviewed
medical records. Diabetic patients with well treated disease may have
normal fasting glucose and HbA1c level. Such cases were then
misclassiﬁed.With this inmindwe still believe that our reference inter-
vals are valuable information for the clinician.
In summary we have determined reference intervals for insulin and
C-peptide not only for a nondiabetic slightly overweight population, but
for a population without prediabetes, according to both WHO and ADA
deﬁnitions. This should make our reference intervals for insulin and C-
peptide for Roche assays widely applicable and more speciﬁc and may
improve clinical practice.
5. Conclusion
This work focused on reference interval for C-peptide and fasting in-
sulin in non-diabetics and prediabetics, the latter according to both the
WHO deﬁnition of PDM and the deﬁnition by ADA. We have generated
reliable reference intervals for C-peptidewhich are ready for implemen-
tation, but for fasting insulin a recertiﬁcation of standards is needed.
Author contributions
• Study concept and design (TH, AL, LFH)
• Acquisition of data (AL, LFH)
• Analysis and interpretation of data (PBL, LFH)
• Drafting of the manuscript (LFH, PBL)
• Critical revision of the manuscript for important intellectual content
(PBL, AL, TH, LFH)
• Statistical analysis (LFH, PBL)
• Obtained funding (AL, LFH)
• Administrative, technical, or material support (LFH)
• Study supervision (LFH, TH).
Acknowledgements
Thework in the authors' laboratorieswas supported by SDC. Roche®
is thanked for supplying reagents.Table 7
Insulin reference interval (AutoDELFIA).
Insulin (pmol/L) 2.5% limit (90% CI),
pmol/L
97.5% limit (90% CI),
pmol/L
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